Novavax has shared positive preliminary results from a real-world study of its JN.1-adapted COVID-19 vaccine. The SHIELD-Utah ...

Novavax (NVAX) closed the most recent trading day at $6.01, moving +0.17% from the previous trading session. This change outpaced the S&P 500's 2.36% loss on the day. Elsewhere, the Dow saw a ...

We expect investors to focus on updates related to Viking Therapeutics’ VKTX pipeline when it reports first-quarter 2025 ...

Shares of Novavax Inc. NVAX shed 3.23% to $6.00 Thursday, on what proved to be an all-around dismal trading session for the ...

One of the FDA’s recently departed top officials is weighing in on the wide-ranging staff cuts at the agency and how they ...

Shares of several vaccine makers soared after reports suggest that the Biden administration is in discussions with Moderna MRNA and Pfizer PFE to set up a possible vaccine program aimed at preventing ...

According to TipRanks, Stranahan is an analyst with an average return of -15.0% and a 32.39% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Candel Therapeutics, ...

Complex Pandemic Accord negotiations have been under way since 2021, with 13 formal meetings and numerous informal sessions.

Yesterday, the US Centers for Disease Control and Prevention (CDC) issued a level 2 travel notice (practice enhanced ...

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

The advisory committee, which met Tuesday for the first time since Robert F. Kennedy Jr. was sworn in as health secretary, ...